Endocrine and Exocrine Secretory Function Alterations After Moderately Severe and Severe Acute Pa… (NCT06590935) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Endocrine and Exocrine Secretory Function Alterations After Moderately Severe and Severe Acute Pancreatitis
China120 participantsStarted 2024-10-08
Plain-language summary
The goal of this observational study is to learn about post-acute pancreatitis diabetes mellitus (PPDM-A). The main questions it aims to answer are:
1. Are the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) after acute pancreatitis of different etiologies the same?
2. Are alterations in endocrine and exocrine secretory function in patients with acute pancreatitis associated with all-round outcomes?
All patients with acute pancreatitis have been given the standardized treatment for the condition.
Investigators will compare the incident rates of glucose metabolic disorders (pre-diabetes and diabetes mellitus) after acute pancreatitis of different etiologies in patients with moderately severe (MSAP) and severe acute pancreatitis (SAP) to explore the association between alterations in endocrine and exocrine secretory function and all-round outcomes.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male or female Chinese subjects;
✓. Age ≥18 years at the time of signing the informed consent;
✓. Patients with a complete diagnosis of MSAP and SAP (according to the Chinese guidelines for the diagnosis and treatment of acute pancreatitis 2019);
✓. Voluntary signatories of informed consent
Exclusion criteria
✕. Patients with a history of diabetes mellitus or pre-diabetes mellitus, or glycosylated hemoglobin ≥ 6.0% or venous FPG ≥ 6.1 mmol/L at admission;
✕. Patients have any evidence of type 1 diabetes-related autoimmunity;
✕. Patients have any risk for secondary diabetes due to exposure to medications or other endocrine diseases;
✕. Combined with pancreas-related trauma or a history of pancreatic surgery;
✕. Patients undergo pancreatic surgery during treatment;
What they're measuring
1
Number of Participants Who developed glucose metabolic disorders (pre-diabetes and diabetes mellitus)
Timeframe: From the AP treatment to 5 years after the end of treatment